Literature DB >> 34608838

Causes and consequences of impaired methionine synthase activity in acquired and inherited disorders of vitamin B12 metabolism.

Jean-Louis Guéant1,2, Rosa-Maria Guéant-Rodriguez1,2, Viola J Kosgei1, David Coelho1.   

Abstract

Methyl-Cobalamin (Cbl) derives from dietary vitamin B12 and acts as a cofactor of methionine synthase (MS) in mammals. MS encoded by MTR catalyzes the remethylation of homocysteine to generate methionine and tetrahydrofolate, which fuel methionine and cytoplasmic folate cycles, respectively. Methionine is the precursor of S-adenosyl methionine (SAM), the universal methyl donor of transmethylation reactions. Impaired MS activity results from inadequate dietary intake or malabsorption of B12 and inborn errors of Cbl metabolism (IECM). The mechanisms at the origin of the high variability of clinical presentation of impaired MS activity are classically considered as the consequence of the disruption of the folate cycle and related synthesis of purines and pyrimidines and the decreased synthesis of endogenous methionine and SAM. For one decade, data on cellular and animal models of B12 deficiency and IECM have highlighted other key pathomechanisms, including altered interactome of MS with methionine synthase reductase, MMACHC, and MMADHC, endoplasmic reticulum stress, altered cell signaling, and genomic/epigenomic dysregulations. Decreased MS activity increases catalytic protein phosphatase 2A (PP2A) and produces imbalanced phosphorylation/methylation of nucleocytoplasmic RNA binding proteins, including ELAVL1/HuR protein, with subsequent nuclear sequestration of mRNAs and dramatic alteration of gene expression, including SIRT1. Decreased SAM and SIRT1 activity induce ER stress through impaired SIRT1-deacetylation of HSF1 and hypomethylation/hyperacetylation of peroxisome proliferator-activated receptor-γ coactivator-1α (PGC1α), which deactivate nuclear receptors and lead to impaired energy metabolism and neuroplasticity. The reversibility of these pathomechanisms by SIRT1 agonists opens promising perspectives in the treatment of IECM outcomes resistant to conventional supplementation therapies.

Entities:  

Keywords:  Methionine synthase; cobalamin; fetal programming; inborn errors of metabolism; peroxisome proliferator-activated receptor-γ coactivator-1α; sirtuin 1; vitamin B12 deficiency

Mesh:

Substances:

Year:  2021        PMID: 34608838     DOI: 10.1080/10409238.2021.1979459

Source DB:  PubMed          Journal:  Crit Rev Biochem Mol Biol        ISSN: 1040-9238            Impact factor:   8.250


  2 in total

1.  Association of H-Type Hypertension with miR-21, miR-29, and miR-199 in Kazahks of Xinjiang, China.

Authors:  Xin He; RuLin Ma; Yu Li; Haixia Wang; YiZhong Yan; YiDan Mao; ShengYu Liao; XueYing Sun; ShuXia Guo; Heng Guo
Journal:  Int J Hypertens       Date:  2022-09-26       Impact factor: 2.434

2.  Methylcobalamin Protects Melanocytes from H2O2-Induced Oxidative Stress by Activating the Nrf2/HO-1 Pathway.

Authors:  Ran An; Dong Li; Yingying Dong; Qiuyun She; Ting Zhou; Xiaoqi Nie; Ronghua Pan; Yunhua Deng
Journal:  Drug Des Devel Ther       Date:  2021-11-30       Impact factor: 4.162

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.